New Haven-based BioXcel Therapeutics has begun treating patients in a trial of its drug designed to treat agitation associated with bipolar disorder and schizophrenia.
Dr. Robert Risinger, chief medical officer, neuroscience at BioXcel, said, “Evaluating BXCL501 [dexmedetomidine] for at-home use is an exciting and important milestone that potentially expands the market opportunity for the treatment of agitation and drives the growth of our neuroscience franchise.”